AI's potential payoff lies in developing better medicines

The rapidly expanding capacity of artificial intelligence is now extending from the digital realm into the physical world, unlocking new potential across various industries. The healthcare sector, in particular, is poised to benefit significantly from AI's ability to enhance drug discovery and development.

U.S. healthcare spending reached approximately $5.3 trillion in 2024, with drug discovery presenting substantial economic potential. AI can streamline this process by reducing unproductive experiments and improving decision-making during the research phase. The success of Eli Lilly's tirzepatide, with sales around $36.5 billion in 2025, illustrates the significant financial value that major pharmaceutical innovations can generate.

AI can assist researchers in prioritizing possibilities, identifying connections within large and diverse datasets, and designing experiments that yield more useful information. While challenges such as limited data and complex biological systems remain formidable obstacles, AI can establish effective learning loops where each experiment refines the next decision.

A persistent failure mode in drug development has been that promising results in models or labs do not always hold up in human trials. AI can improve the odds of success in clinical trials and lead to better patient outcomes. Successful AI-enabled drug discovery could justify the current scale of AI investment by delivering breakthroughs more frequently and accelerating their arrival to patients, granting millions more healthy years of life.